A female baseline panel is harder to get right than a male one because the “right” panel changes with the patient’s reproductive stage, cycle day and symptoms. Order the male panel with a few swaps and you will miss what matters; order everything and you will spend $700 on numbers that cannot be interpreted. This is how the operating team structures the female baseline across our clinics: a core panel for everyone, a stage-specific layer, and timing rules that make the results mean something.
Start with stage, not symptoms
Before ordering, classify the patient:
- Cycling (regular periods, typically under 45): hormones vary by cycle day, so timing is everything.
- Perimenopausal (irregular cycles, vasomotor or sleep symptoms, typically 40–55): single-day hormone values are unreliable; the clinical picture carries more weight.
- Postmenopausal (12 months without a period, or surgical): values are stable and interpretable on any day.
- On hormonal contraception: most sex-hormone values are uninterpretable; order the metabolic and thyroid core and plan hormone labs after a documented washout if appropriate.
Record the stage and last menstrual period in the intake form so staff can time the draw correctly. The Institute’s clinic operations playbook covers how that intake field drives the lab scheduling text.
The core panel (every new female patient)
| Test | Why it is on the panel | Note |
|---|---|---|
| Estradiol | Primary estrogen; baseline for therapy and symptom correlation | Sensitive assay preferred in postmenopausal women where values are low |
| Progesterone | Confirms ovulation in cycling women; baseline before progesterone therapy | Draw day 19–22 of a 28-day cycle; any day postmenopause |
| FSH and LH | Supports menopausal status; FSH rises as ovarian reserve declines | Day 2–4 in cycling women; unreliable in perimenopause |
| Total testosterone and SHBG | Low libido, energy and muscle loss; SHBG rises with oral estrogen | Calculate free T; female reference ranges |
| DHEA-S | Adrenal androgen precursor; declines with age | Informs DHEA supplementation decisions |
| TSH, free T4, free T3 | Thyroid disorders are far more common in women and mimic hormone symptoms | Add TPO antibodies if TSH is borderline or family history |
| CBC | Anemia from heavy bleeding; general baseline | Add ferritin if heavy periods or fatigue |
| CMP | Liver and kidney function before any oral hormone | Fasting |
| Lipid panel | Cardiometabolic baseline; route of estrogen affects lipids | Fasting |
| HbA1c and fasting insulin | Insulin resistance underlies PCOS and perimenopausal weight gain | Changes the whole plan when abnormal |
| Vitamin D, 25-OH | Bone health and mood; common deficiency | Quick, visible win |
Stage-specific additions
Cycling women with irregular cycles or androgen symptoms
Add free testosterone by dialysis, 17-OH progesterone (to screen for non-classic adrenal hyperplasia), prolactin, and consider AMH for ovarian reserve context. A PCOS workup also needs a documented clinical assessment, not labs alone.
Perimenopausal women
Resist the urge to chase hormone values. Order the core for safety and metabolic context, document symptoms with a validated scale, and treat the clinical picture. Repeat estradiol and FSH only if the diagnosis is genuinely unclear.
Postmenopausal women
The core panel is usually sufficient. Confirm an up-to-date mammogram and cervical screening per guidelines before starting systemic estrogen, and document the shared decision about timing, route and progesterone protection for women with a uterus.
Women considering testosterone
Baseline total testosterone and SHBG are essential since testosterone for women is off-label in the US; your consent and note must state the baseline value, the target range you intend to stay within, and the monitoring plan.
What to leave out of the first draw
Urine hormone metabolite panels, salivary cortisol curves, comprehensive micronutrient panels and food sensitivity tests are second-tier offerings, not baseline. They make sense for selected established patients and should be priced and consented separately.
Timing rules staff must follow
- Cycling patient: schedule the draw for day 19–22 if progesterone matters most, or day 2–4 if FSH/estradiol matters most. Do not try to get both from one draw; pick based on the chief complaint and document why.
- Morning and fasting for the metabolic tests regardless of cycle day.
- No biotin supplements for 48–72 hours before the draw (interferes with many immunoassays, including thyroid).
- Record cycle day and LMP on the requisition.
Pricing the female baseline
Through a direct-bill account with a national reference lab, reasonable 2026 wholesale estimates for the core panel run about $110–$220, with the stage-specific additions adding $20–$80. Retail at patient-pay prices is often several times that. Most of our clinics price the female baseline the same way as the male baseline so the pricing page stays simple: either bundled into a $250–$500 enrollment fee or listed as a $249–$399 lab fee. State it clearly up front; the Institute’s free clinic launch checklist includes the pricing-page and financial-consent items that keep lab fees from becoming surprises.
Interpreting with the note
Document the stage, cycle day, symptom scale score, the values you relied on, the screening status (mammogram, cervical, bone density where relevant), and the decision. For hormone therapy in women, the quality of that paragraph matters more than any single lab value.
FAQ
Do I need hormone labs to treat a clearly menopausal woman?
Diagnosis is clinical in a woman over 45 with classic symptoms and 12 months without a period. The baseline panel still matters for safety and metabolic context, and for tracking the effect of therapy.
Which cycle day should I pick if the patient only wants one draw?
Decide by the chief complaint: luteal (day 19–22) when the question is progesterone or PMS-type symptoms; early follicular (day 2–4) when the question is ovarian reserve or estrogen status. Document the reasoning.
Should the female baseline include a PSA-equivalent screening?
There is no lab equivalent; the safety screens for systemic estrogen are mammography, cervical screening and clinical history. Confirm they are current and documented before the first prescription.
CLINIC IN A BOX™
Build your telemedicine clinic in 12 weeks — with an operator beside you
Clinic In A Box™ is a private, 1-on-1, done-with-you build: entity, licensing, EHR, labs, pharmacy, pricing, patient acquisition — and your first patients seen by week 12. Limited spots per quarter.